Norges Bank Acquires New Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Norges Bank purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 292,746 shares of the medical equipment provider's stock, valued at approximately $26,189,000. Norges Bank owned about 0.42% of Lantheus at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new position in Lantheus in the fourth quarter valued at $27,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Lantheus by 118.0% during the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock worth $91,000 after buying an additional 551 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 64,109 shares of company stock worth $6,110,806. Company insiders own 1.50% of the company's stock.

Lantheus Stock Performance

NASDAQ:LNTH traded up $3.49 during trading hours on Friday, hitting $102.00. The company's stock had a trading volume of 732,023 shares, compared to its average volume of 955,016. Lantheus Holdings, Inc. has a 52-week low of $59.56 and a 52-week high of $126.89. The business's 50-day moving average is $94.00 and its two-hundred day moving average is $95.62. The company has a market capitalization of $6.98 billion, a PE ratio of 16.97 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent research reports. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Finally, JMP Securities reissued a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Lantheus has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.